Oncimmune’s CEO Martin Gouldstone joined Steve Darling from Proactive Investor to announce the company’s interim results for the six months ended February 29, 2024. During this period, Oncimmune achieved revenue of £1.19 million, marking a significant milestone in the company’s financial performance. Martin Gouldstone expressed satisfaction with the company’s performance in the first half of fiscal year 2024, highlighting the substantial increase in revenues compared to the ImmunoINSIGHTSTM business in fiscal year 2023. This achievement underscores the effectiveness of Oncimmune’s new strategic approach and commercial endeavors, which are gaining momentum. Moreover, Gouldstone revealed that Oncimmune secured contracts for seven new projects during the reporting period. These contracts are expected to be completed by the end of fiscal year 2024, contributing to the company’s revenue growth trajectory. Additionally, Oncimmune entered into a Master Services Agreement with Freenome, further enhancing its commercial portfolio. View the interview below:
CEO, Martin Gouldstone speaks to Proactive London about the the company’s six month interim results.
28 May 2024